Shanghai, China & Incheon, South Korea – Phrontline Biopharma, a clinical-stage biotechnology company dedicated to developing a new generation of Antibody-Drug Conjugates (ADCs), today announced it has entered a global strategic collaboration with Samsung Bioepis Co., Ltd. to jointly develop best-in-class ADC therapies for the treatment of solid tumors.

SHANGHAI and SUZHOU, China, Sept. 14, 2025 /PRNewswire/ -- Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company's lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology.

Phrontline Biopharma is pleased to announce that its first bispecific ADC program, TJ101, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). This milestone marks the company’s official transition into the clinical stage, showcasing its strong R&D capabilities in the ADC field and offering new therapeutic hope to patients worldwide.

Phrontline Biopharma has announced the completion of its Pre-A funding round, raising over 100 million RMB. This capital infusion will accelerate R&D investment, advance multiple preclinical programs, upgrade proprietary technology platforms, and expedite the company’s journey toward becoming a globally leading biopharmaceutical innovator.